Pair page
Pentapeptide-18 with Syn-Coll
Mechanism-tag overlap and published literature for Pentapeptide-18 and Syn-Coll, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Pentapeptide-18 unique
enkephalin-analog
Shared
cosmetic-peptide
Syn-Coll unique
tgf-mimetic-collagen-signal
Quick facts
Pentapeptide-18
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A — topical cosmetic
Syn-Coll
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient (not drug)
WADAN/A (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2013 | Pentapeptide-18 | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23435580. (Placebo-controll… PMID 23435580 | human trial |
| 2014 | Pentapeptide-18 | Dragomirescu AO, Andoni M, Ionescu D, Andrei F. The Efficiency and Safety of Leuphasyl—A Botox-Like Peptide. Cosmetics. 2014;1(2):75-81. doi:10.3390/cosmetics1020075. (Only peer-reviewed open-label human efficacy paper specific to Pentapeptide-18; manufacturer-adjacent but metho… | human pilot |
| 1999 | Pentapeptide-18 | Acosta CG, López HS. delta opioid receptor modulation of several voltage-dependent Ca(2+) currents in rat sensory neurons. J Neurosci. 1999 Oct 1;19(19):8337-8348. doi:10.1523/JNEUROSCI.19-19-08337.1999. PMID: 10493736; PMCID: PMC6783030. (Direct electrophysiological evidence th… PMID 10493736 | preclinical, in vivo |
| 2015 | Pentapeptide-18 | Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi:10.3109/15569527.2014.894521. PMID: 24641245. (Permeation analog study — demonstrates that ~0.22% of topically a… PMID 24641245 | preclinical, in vitro |
| 2002 | Pentapeptide-18 | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi:10.1046/j.1467-2494.2002.00153.x. PMID: 1849852… PMID 18498523 | mechanism / discovery |
| 1975 | Pentapeptide-18 | Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975 Dec 18;258(5536):577-580. doi:10.1038/258577a0. PMID: 1207728. (The landmark Hughes & Kosterlitz p… PMID 1207728 | mechanism / discovery |
| 1977 | Pentapeptide-18 | Hughes J, Kosterlitz HW, Smith TW. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol. 1977 Dec;61(4):639-647. doi:10.1111/j.1476-5381.1977.tb07557.x. PMID: 597668. (Follow-up Hughes/Kosterlitz distribution paper… PMID 597668 | pharmacology |
| 2024 | Pentapeptide-18 | Cullen JM, Cascella M. Physiology, Enkephalin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 32491696. (Comprehensive physiology review of enkephalin structure, receptor pharmacology, and degradation — useful pharmacology reference for the Leuph… PMID 32491696 | review |
| 2022 | Pentapeptide-18 | Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022 Apr;44(2):232-248. doi:10.1111/ics.12770. PMID: 35152433. (Independent review of the skin-permeation bottleneck that constrains all topical anti-wrinkl… PMID 35152433 | review |
| 2012 | Pentapeptide-18 | Reddy B, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012 Aug;21(8):569-575. doi:10.1111/j.1600-0625.2012.01528.x. PMID: 22775991. (Dermatology-journal review of bioactive cosmetic oligopeptides including the neurotransmitter-affecting peptid… PMID 22775991 | review |
| 2009 | Pentapeptide-18 | Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009 Sep-Oct;27(5):485-494. doi:10.1016/j.clindermatol.2009.05.013. PMID: 19695481. (Foundational dermatology-journal review of cosmeceutical peptides that contextualizes Leuphasyl within the neurotransmitter-affecti… PMID 19695481 | review |
| 2005 | Pentapeptide-18 | Lipotec S.A. LEUPHASYL®: A New Pentapeptide for Expression Wrinkles. Technical dossier / formulator brochure. Barcelona: Lipotec; 2005. (Originator manufacturer dossier, widely re-cited across cosmetic industry literature; source of the 11.64% stand-alone and 24.62% Leuphasyl +… | industry documentation |
| 1998 | Syn-Coll | Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93(7):1159-1170. doi:10.1016/s0092-8674(00)81460-9. PMID: 9657149. (Genetic demonstration in TSP-1-null mice th… PMID 9657149 | preclinical, in vivo |
| 1987 | Syn-Coll | Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987;247(3):597-604. doi:10.1042/bj2470597. PMI… PMID 3501287 | preclinical, in vitro |
| 2004 | Syn-Coll | Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem. 2004;279(36):38032-38039. doi:10.1074/jbc.M405658200. PMID: 15208302. (Biochemical characterization of the LAP "latency lasso" that TSP-1 KRFK disrupts.) PMID 15208302 | mechanism / discovery |
| 1992 | Syn-Coll | Murphy-Ullrich JE, Schultz-Cherry S, Höök M. Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell. 1992;3(2):181-188. doi:10.1091/mbc.3.2.181. (Original biochemical characterization of the TSP-1 / TGF-β complex.) | mechanism / discovery |
| 1986 | Syn-Coll | Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261(9):4337-4345. PMID: 3456347. (Early demonstration of TGF-β–driven matrix gene expression; co-… PMID 3456347 | mechanism / discovery |
| 2018 | Syn-Coll | Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease. Matrix Biol. 2018;68-69:28-43. doi:10.1016/j.matbio.2017.12.009. (Comprehensive modern review of TSP-1 / TGF-β targeting for disease; PMC6015530.) | review |
| 2007 | Syn-Coll | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (The most widely cited dermatology review of cosmeceutical peptides; positions palmitoyl tripeptide-5 within the signal-peptide class.) PMID 18045359 | review |
| 2000 | Syn-Coll | Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11(1-2):59-69. doi:10.1016/s1359-6101(99)00029-5. PMID: 10708953. (Definitive mechanistic review of TSP-1-dependent TGF-β activation.) PMID 10708953 | review |
| — | Syn-Coll | Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides and Palmitoyl Polypeptides as Used in Cosmetics. Int J Toxicol. CIR Final Report (periodic updates). (Regulatory safety review of the palmitoyl-peptide class, including palmitoyl tripeptide-5.) | review |
| 2009 | Syn-Coll | Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Dermatol Clin. 2009;27(4):401-416, v. doi:10.1016/j.det.2009.05.006. PMID: 19850190. (Dermatology practice-level overview of cosmeceutical peptide use, including TGF-β–mimetic tripeptides.) PMID 19850190 | research article |
| 2004 | Syn-Coll | Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem. 2004;279(46):47633-47642. doi:10.1074/jbc.M404918200. PMID: 15347654. (Identification of the WxxW "do… PMID 15347654 | research article |
| 1999 | Syn-Coll | Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem. 1999;274(19):13586-13593. doi:10.1074/… PMID 10224129 | research article |
Related pair pages
More research context
Frequently asked
Have Pentapeptide-18 and Syn-Coll been studied together?
No co-administration studies between Pentapeptide-18 and Syn-Coll are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Pentapeptide-18 and Syn-Coll share?
Pentapeptide-18 and Syn-Coll share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Pentapeptide-18 and Syn-Coll?
Pentapeptide-18: Cosmetic ingredient. Syn-Coll: Cosmetic ingredient (not drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Pentapeptide-18 and Syn-Coll?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Pentapeptide-18 profile and the Syn-Coll profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026